



# FINAL PROGRAM

## 2017 ANNUAL MEETING

*Immune Deficiency & Dysregulation North American Conference*  
March 23-26, 2017 • The Westin Seattle • Seattle, Washington

**CIS** Clinical  
Immunology  
Society

## ABOUT CIS

The Clinical Immunology Society (CIS), established in 1986, is the key interdisciplinary organization for the field of clinical immunology and is devoted to fostering developments in the science and practice of clinical immunology. CIS is an international professional organization which includes more than 900 clinicians, investigators, and trainees.

The mission of CIS is to facilitate education, translational research and novel approaches to therapy in clinical immunology to promote excellence in the care of patients with immunologic/inflammatory disorders.

The primary objectives and purposes of CIS are to:

- facilitate the interchange of ideas and information among physicians and other investigators who are concerned with immunological/inflammatory diseases;
- promote research on the causes and mechanisms of diseases relating to the immune system and, as a result, to unify concepts of disease pathogenesis;
- encourage investigators and clinicians to share in their knowledge of immunologically active drugs and other interventions;
- promote application and dissemination of recent advances in biomedical science for the prevention, diagnosis and treatment of diseases related to immunity and inflammation; and
- foster excellence in research and medical practice.

## CIS NATIONAL OFFICE

555 East Wells Street, Suite 1100  
Milwaukee, WI 53202  
Phone: 414.224.8095  
E-mail: [info@clinimmsoc.org](mailto:info@clinimmsoc.org)  
[www.clinimmsoc.org](http://www.clinimmsoc.org)

## 2017 ANNUAL MEETING PROGRAM COMMITTEE

### CO-CHAIRS:

**Jordan S. Orange, MD, PhD**

Baylor College of Medicine  
Houston, TX

**Roshini Sarah Abraham, PhD**

Mayo Clinic  
Rochester, MN

### COMMITTEE:

**Steven M. Holland, MD**

NIAID, NIH  
Bethesda, MD

**Sergio Rosenzweig, MD, PhD**

NIAID, NIH  
Bethesda, MD

**Kathleen E. Sullivan, MD, PhD**

Children's Hospital of Philadelphia  
Philadelphia, PA

**Troy R. Torgerson, MD, PhD**

University of Washington  
Seattle, WA

## TABLE OF CONTENTS

About CIS.....	1
General Meeting Information.....	3
Continuing Medical Education Information .....	4
Speakers Disclosures .....	5
Seattle Visitor Information .....	6
Schedule At-A-Glance .....	7
Schedule of Events.....	8
Exhibit Hall Floor Plan .....	15
Exhibitor Listing .....	17
Poster Listing .....	18
2017 Annual Meeting Supporters .....	24

## CONNECT WITH YOUR COLLEAGUES!

"LIKE" CIS on Facebook

Follow us on Twitter @CLINIMMSOC #CIS2017 #CISinSeattle

Join our Group on LinkedIn



**President**

**Jordan S. Orange, MD PhD**  
Baylor College of Medicine

**Past President**

**Luigi D. Notarangelo, MD**  
NIAID, NIH

**President-Elect**

**Roshini Sarah Abraham, PhD**  
Mayo Clinic

**Secretary-Treasurer**

**Daniel C. Adelman, MD**  
University of California, San Francisco

**Elected Councilors**

**Troy Torgerson, MD PhD**  
University of Washington

**Sergio D. Rosenzweig, MD PhD**  
NIAID, NIH

**Appointed Councilors**

**Alexandra F. Freeman, MD**  
NIAID, NIH

**Elie Haddad, MD PhD**  
University of Montreal

**Elena E. Perez, MD PhD**  
University of Miami School of Medicine

**James Verbsky, MD PhD**  
Medical College of Wisconsin

**Editor in Chief, *Journal of Clinical Immunology***

**Vincent R. Bonagura, MD**  
Alexandra and Steven Cohen Children's Medical Center of NY

**Website Medical Editor**

**Zoulfia Allakhverdi, PhD**  
CHU Ste-Justine Hospital

Dear Colleagues,

On behalf of the Clinical Immunology Society (CIS), thank you for participating in the 2017 Annual Meeting: Immune Deficiency & Dysregulation North American Conference taking place March 23-26, 2017 at The Westin Seattle in Seattle, Washington.

CIS is the key inter-disciplinary organization for the field of clinical immunology and is devoted to fostering developments in the science and practice of clinical immunology. The mission of CIS is to facilitate education, translational research and novel approaches to therapy in clinical immunology and to promote excellence in the care of patients with immunologic/inflammatory disorders.


The CIS leadership and the members of the Program Committee have jointly defined our goals and have engaged clinicians and researchers from all types of backgrounds to try to identify the best manner of addressing the critical needs. The primary goal of the Annual Meeting is to provide an exciting venue for the presentation of the newest immune deficiency diseases and the pathogenesis of these defects in molecular terms. The substance of the conference will be cutting edge clinical and basic science research. Another goal is to educate clinicians regarding state of the art clinical care. We recognize that physicians in training who are likely to see these patients need sessions on the pragmatic aspects of diagnosis and clinical care; thus sessions were designed to provide a stimulating discussion of these issues, while delving into unsolved questions. The final major goal of this conference is to begin to grow the community of physicians who feel competent to see patients with primary immune deficiency. We believe that this is the only way to consolidate and build up a community of physicians and scientists who are working in this area. This Annual Meeting is sure to foster enthusiasm and provide advanced training for physicians and researchers working in the field of primary immune deficiency.

The CIS leadership is excited about the 2017 Annual Meeting and we look forward to bringing accomplished clinical researchers together to present what is sure to be outstanding science. We hope you enjoy the meeting!

Regards,



Jordan S. Orange, MD, PhD  
Baylor College of Medicine  
Houston, TX  
2017 Program Committee Co-Chair



Roshini Sarah Abraham, PhD  
Mayo Clinic  
Rochester, MN  
2017 Program Committee Co-Chair



# Submit a Manuscript

The *Journal of Clinical Immunology* accepts manuscripts in the areas of human, basic, and clinical immunology and molecular biology. The areas of basic immunology include (but are not limited to) studies of lymphocytes, antigen presenting cells, neutrophils, natural killer cells, complement components, immunoglobulins, antibodies, cytokines and their receptors, immunoregulation, signal transduction, T-cell receptors, and immunoglobulin genes. Papers on animal models of human diseases are welcome. Articles dealing with molecular biology related to human diseases are accepted. Special Articles are by invitation only. Case reports will only be considered if they are linked to novel new findings/science or are accompanied by an extensive review of the relevant medical literature to the findings of the case report.

Authors, editors and reviewers of *Journal of Clinical Immunology* use our fully web-enabled online manuscript submission and review system. To keep the review time as short as possible, we request authors to submit manuscripts online to the journal's editorial office. Our online manuscript submission and review system offers authors the option to track the progress of the review process of manuscripts in real time.

# About the Journal

The *Journal of Clinical Immunology* is a bimonthly international journal that helps researchers and academic clinicians keep current on investigative basic immunology and diseases related to the immune system. This well-established journal publishes articles on basic, translational, and clinical studies in all aspects of immunology, including animal models of human diseases.

The OnlineFirst™ feature allows articles to be viewed through the journal's website before they are available in the printed journal. The *Journal of Clinical Immunology* is the official journal of the Clinical Immunology Society.



To submit a manuscript, please visit <http://www.editorialmanager.com/joci/>

## Editor-in-Chief:

Vincent R. Bonagura  
The Feinstein Institute for  
Medical Research  
Hofstra North Shore-LIJ  
School of Medicine  
Manhasset, NY, USA

## Deputy Editor:

Jean-Laurent Casanova  
The Rockefeller University  
New York, NY, USA

## Managing Editor:

David W. Rosenthal  
Hofstra North Shore-LIJ  
School of Medicine  
Manhasset, NY, USA

## Associate Editors:

Steven M. Holland  
National Institute of Allergy  
and Infectious Diseases  
Bethesda, MD, USA

Christoph Klein  
Ludwig Maximilians  
University Munich  
Munich, Germany

László Maródi  
University of Debrecen  
Debrecen, Hungary

Luigi D. Notarangelo  
Boston Children's Hospital  
Harvard University  
Boston, MA, USA

Lawrence Schwartz  
Virginia Commonwealth  
University  
Richmond, VA, USA

Ricardo Sorensen  
Louisiana State University  
Health Science Center  
New Orleans, LA, USA

Helen C. Su  
National Institute of Allergy  
and Infectious Disease  
Rockville, MD, USA

Stuart Tangye  
Garvan Institute of Medical  
Research  
Sydney, NSW, Australia

Troy R. Torgerson  
Seattle Children's Hospital  
Seattle, WA, USA

## Editorial Board:

Daniel Adelman  
University of California at San  
Francisco  
San Francisco, CA, USA

Waleed Al-Herz  
Kuwait University  
Kuwait

Hamoud Al-Moussa  
King Faisal Specialist Hospital  
and Research Center  
Riyadh, Saudi Arabia

Saleh Al-Muhsen  
King Saud University  
Riyadh, Saudi Arabia

Basel K. Al-Ramadi  
United Arab Emirates  
University  
United Arab Emirates

Mohamed Ridha Barbouche  
Institute Pasteur de Tunis  
Tunis, Tunisia

Mel Berger  
CSL Behring  
Cleveland, OH, USA

Francisco Bonilla  
Harvard University Children's  
Hospital  
Boston, MA, USA

Aziz Bousfiha  
King Hassan II University  
Casablanca, Morocco

Kaan Boztug  
Medical University of Vienna  
Vienna, Austria

Yenan Bryceson  
Karolinska Institutet  
Stockholm, Sweden

Yildiz Camcioglu  
Istanbul University  
Istanbul, Turkey

Regis Campos  
Federal University of Bahia  
Medical School  
Salvador, Brazil

Fabio Candotti  
National Human Genome  
Research Institute  
Bethesda, MD, USA

Andrew Cant  
Newcastle University  
Newcastle upon Tyne, United  
Kingdom

Talal Chatila  
University of California at Los  
Angeles  
Los Angeles, CA, USA

Antonio Condino-Neto  
University of São Paulo  
São Paulo, Brazil

Beatriz Tavares Costa-  
Carvalho  
Federal University of São  
Paulo  
São Paulo, Brazil

Charlotte Cunningham-  
Rundles  
Mount Sinai Medical Center  
New York, NY, USA

Silvia Danielian  
Hospital de Pediatria Pr Dr  
Juan P Garrahan  
Buenos Aires, Argentina

Stephan Ehl  
University of Freiburg  
Freiburg, Germany

Francisco Espinosa  
Instituto Nacional de Pediatría  
Mexico

Amos Etzioni  
Ruth Rappaport Children's  
Hospital  
Haifa, Israel

Lisa Filipovich  
Cincinnati Children's Hospital  
Medical Center  
Cincinnati, Ohio, USA

Jose Luis Franco  
Universidad de Antioquia  
Medellin, Columbia

Benzi Garty  
Schneider Children's Medical  
Center of Israel and Tel Aviv  
University School of Medicine  
Tel Aviv, Israel

Bobby Gaspar  
University College London  
London, United Kingdom

Andrew Gennery  
Newcastle University  
Newcastle upon Tyne, United  
Kingdom

Anete Grumach  
Alameda Santos  
São Paulo, Brazil

Sophie Hambleton  
Newcastle University  
Newcastle upon Tyne, United  
Kingdom

Lennart Hammarstrom  
Karolinska Institute  
Stockholm, Sweden

Hal Hoffman  
University of California at  
San Diego  
San Diego, CA, USA

Jamie Inostroza  
University of La Frontera  
Temuco, Chile

Stephen Jolles  
Cardiff University  
Cardiff, United Kingdom

Emmanuelle Jouanguy  
INSERM  
Paris, France

Carl June  
University of Pennsylvania  
School of Medicine  
Philadelphia, PA, USA

Donald Kohn  
University of California at Los  
Angeles  
Los Angeles, CA, USA

Necil Kütükçüler  
Ege University Medical School  
Ege, Turkey

Harry Malech  
National Institute of Allergy  
and Infectious Diseases  
Bethesda, MD, USA

Tim Niehues  
HELIOS Klinikum Krefeld  
Krefeld, Germany

Joao Bosco Oliveira  
National Institute of Health  
Bethesda, MD, USA

Jordan Orange  
Texas Children's Hospital  
Houston, TX, USA

Qiang Pan-Hammarstrom  
Karolinska Institutet  
Stockholm, Sweden

Rebeca Perez de Diego  
IdiPAZ  
La Paz, Spain

Alessandro Plebani  
Università degli studi de  
Brescia  
Brescia, Italy

Jennifer Puck  
University of California at San  
Francisco  
San Francisco, CA, USA

Anne Puel  
INSERM  
Paris, France

Jose R. Regueiro  
Universidad Complutense  
Madrid  
Madrid, Spain

Janine Reichenbach  
University Children's Hospital  
Zurich  
Zurich, Switzerland

John Routes  
Medical College of Wisconsin  
Milwaukee, WI, USA

Reinhard Seger  
University Children's Hospital  
Zurich  
Zurich, Switzerland

John W. Sleasman  
Duke University School of  
Medicine  
Durham, NC, USA

Mirjam van der Burg  
Erasmus  
Rotterdam, The Netherlands

Dewton de Moraes  
Vasconcelos  
University of São Paulo  
Medical School  
São Paulo, Brazil

Anna Villa  
Institute of Genetic and  
Biomedical Research  
Italy

Horst von Bernuth  
University of Berlin  
Berlin, Germany

## Founding Editor:

Sudhir Gupta  
University of California at  
Irvine  
Irvine, CA, USA

## MEETING LOCATION

All educational sessions, posters, exhibits, and registration held as part of the CIS Annual Meeting will take place at the The Westin Seattle.

The Westin Seattle  
1900 5th Avenue  
Seattle, WA, 98101  
P: 206-728-1000

### Exhibit Hall

The Westin Seattle ~ Grand Ballroom II and III

Exhibitors provide the latest information on products and services available to physicians, researchers and allied health professionals in the field of immunology. Take this valuable opportunity to meet with companies and organizations specializing in all areas of the immunology field.

### Exhibitor Move-In

Thursday March 23  
8:00am – 5:00pm

### Exhibit Hours

Friday, March 24th  
12:30pm – 2:00pm & 6:00pm – 7:00pm  
Saturday, March 25th  
12:30pm – 2:00pm & 5:00pm – 7:00pm

### Exhibitor Move-Out

Saturday, March 25th  
7:00pm – 10:00pm

## POSTER SESSIONS

Poster sessions are held in the Grand Ballroom II and III, and authors will be present with their posters from 1:30pm to 2:00pm Friday, March 24 and Saturday, March 25. Lunch will be available in the Grand Foyer during the exhibit hall opening and poster session hours.

## PUBLISHING OF ABSTRACTS

The abstracts submitted to the 2017 Annual Meeting are published in the April issue of *Journal of Clinical Immunology*, the official journal of the Clinical Immunology Society. Copies are available at the CIS registration desk.

## ACCESSIBILITY

If you require special arrangements in order to fully participate in the CIS Annual Meeting, please speak with a CIS staff member at the registration desk.

## NAME BADGES

All registered attendees at the CIS Annual Meeting will receive a name badge as part of their registration packet. These badges should be worn at all times as they will be used to control access to sessions and activities.

## SMOKING

Smoking is prohibited at all CIS Annual Meeting sessions and events.

## EVALUATIONS

Delegates will have the opportunity to provide feedback on their experience at the 2017 CIS Annual Meeting. After the meeting all registered delegates will receive an online evaluation to complete. Evaluations are an important part in helping us to improve our educational sessions so please take a moment to complete it!

## LISTSERV

### CIS-PIDD LIST SERVICE & ECI LIST SERVICE

The E-mail CIS-PIDD service has been set up to provide an easy way for CIS members to discuss issues of common interest. The E-mail ECI List Service has been set up to provide fellows and junior faculty a dedicated place to discuss issues with each other; it is limited to Fellows-in-Training, Junior Faculty and a few select Senior Faculty members for mentor purposes. The server group may also be used to look for collaborators or new faculty members. These List Services are set up as a communication tool to help you interact with your colleagues. It is closed to the general public. Visit [www.clinimmsoc.org](http://www.clinimmsoc.org) to sign up.

## REGISTRATION DESK

The Westin Seattle ~ Grand Foyer

### Registration Desk Hours

Wednesday, March 22	4:00pm – 7:00pm
Thursday, March 23	7:00am – 7:00pm
Friday, March 24	7:00am – 7:00pm
Saturday, March 25	7:00am – 7:00pm
Sunday, March 26	7:00am – 10:30am

## CONTINUING MEDICAL EDUCATION INFORMATION

### PURPOSE

Provide an opportunity for physicians to receive updated information and solidify their knowledge of primary immune deficiency.

### CONTENT AREA

The content will cover practical, cutting edge and theoretical issues related to patient care. The majority of the immune deficiencies will be covered to provide the maximal educational experience.

### TARGET AUDIENCE

Physicians, scientists and nurses who are involved in the evaluation and/or care of patients with primary immune deficiencies. Participants should be pediatricians, internists, or scientists committed to the clinical management of patients with primary immunodeficiency diseases. These candidates may have backgrounds in immunology, adult medicine, rheumatology, hematology, laboratory immunology, or allergy/immunology.

### LEARNING OBJECTIVES

At the completion of the activity, participants should be able to:

- Recognize the value of new research techniques;
- Describe new research findings in immunology;
- Explain the diagnosis and management of diseases and disorders across various subspecialties of medicine.

### ACCME ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of the Clinical Immunology Society (CIS). The CIS is accredited by the ACCME to provide continuing medical education for physicians.

### DESIGNATION STATEMENT

The Clinical Immunology Society designates this live activity for a maximum of 20 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### CLAIMING CME

To claim CME credit and print out your CME certificate and/or certificate of attendance, please visit <http://www.clinimmsoc.org/cme/am17/>.





## DISCLOSURES OF CONFLICT OF INTEREST

### 2017 ANNUAL MEETING PROGRAM COMMITTEE AND SPEAKER DISCLOSURES

The Clinical Immunology Society (CIS) require instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved. The existence or absence of COI for everyone in a position to control content appears below.

**Andrew Cant, MD**

GREAT NORTH CHILDREN'S HOSPITAL  
Sanofi Pasteur MSD – Consultant receiving consulting fee

**Charlotte Cunningham-Rundles, MD, PhD**

MOUNT SINAI MEDICAL CENTER  
Momenta – Consultant receiving consulting fee  
Biotest – Consultant receiving consulting fee  
ADMA – Consultant receiving consulting fee

**Chris Wilson, MD**

Venrock – Consultant receiving consulting fee  
Avalon Ventures – Consultant receiving consulting fee

**Daniel Campbell, PhD**

BENAROYA RESEARCH INSTITUTE  
No Disclosure Received

**Elie Haddad, MD, PhD**

CHU SAINT-JUSTINE, UNIVERSITY OF MONTREAL  
CSL Behring – Investigator Initiated Grant – Principal Investigator  
Sigma-Tau – Consultant receiving consulting fee

**Isabelle Meyts, MD, PhD**

UNIVERSITY HOSPITALS LEUVEN  
CSL-Behring – Honoraria for speaking and teaching; Research grant recipient  
Steripolar – Honoraria for speaking and teaching  
Baxalta/Shire – Research Grant Recipient

**Jared Silver, MD, PhD**

BRIGHAM AND WOMEN'S HOSPITAL AND  
HARVARD MEDICAL SCHOOL  
Grifols – Research Grant Recipient

**Jean-Laurent Casanova, MD, PhD**

THE ROCKEFELLER UNIVERSITY  
Neovacs – Consultant receiving consulting fee  
ADMA – Membership on advisory committee or review committee; Consultant receiving consulting fee  
Nimbus – Independent contractor receiving consulting fee  
Vitae Pharmaceuticals, Inc – Independent contractor receiving consulting fee

**Jordan Orange, MD, PhD**

BAYLOR COLLEGE OF MEDICINE  
ADMA – Membership on Advisory Committee or Review Committee; Consultant receiving honoraria  
CSL Behring – Consultant receiving honoraria  
Shire – Consultant receiving honoraria  
Grifols – Consultant receiving consulting fee

**Lauri Burroughs, MD**

UNIVERSITY OF WASHINGTON SCHOOL OF  
MEDICINE  
Medac GmbH--Provides Treosufin for study and funds to help run clinical trial

**Lennart Hammarström, MD, PhD**

KAROLINSKA INSTITUET  
Beijing Genomics – Consultant receiving consulting fee  
Mabtech Diagnostics – Stock purchased – Scientific Advisor

**Lori Broderick, MD, PhD**

UNIVERSITY OF CALIFORNIA, SAN DIEGO  
NIH – Research grant recipient

**Manish Butte, MD, PhD**

UCLA MEDICAL CENTER  
Allertope, Inc. – Co-founder with no operational role receiving ownership interests  
Microvolution, LLC – Co-founder with no operational role ownership interests  
Alpine Immune Sciences – Scientific Advisory Board with no operational role receiving ownership interests  
EpikaBio – Co-founder with no operational role receiving ownership interests  
Chimera Bio – Scientific Advisory Board with no operational role receiving ownership interests

**Markus Seidel, MD**

MEDICAL UNIVERSITY OF GRAZ  
Baxalta/Shire – Speaking and Teaching; Membership on advisory committee or review committee with Honoraria  
Novartis – Speaking and Teaching; Membership on advisory committee or review committee with honoraria

**Michael Jensen, MD**

SEATTLE CHILDREN'S RESEARCH INSTITUTE  
Juno Therapeutics, Inc. – Consultant receiving consulting fee; Membership on advisory committee or review committee receiving Intellectual property rights and ownership interest

**Mikko Seppänen, MD, PhD**

HELSINKI UNIVERSITY HOSPITAL  
CSL Behring – Speaking and Teaching receiving honoraria  
Octapharma – Speaking and Teaching receiving honoraria

**Monica Lawrence, MD**

UNIVERSITY OF VIRGINIA  
Merck – Member of clinical trial events adjudication committee receiving consulting fee  
Pharmacosmos – Member of clinical trial events adjudication committee receiving consulting fee

**Ricardo Sorensen, MD**

LSU HEALTH SCIENCES CENTER  
CSL Behring – Speaker fee for speaking  
Shire/Baxalta – Investigator initiated research project support

**Stuart Tangye, PhD**

UNIVERSITY OF NSW, AUSTRALIA  
Jeffrey Modell Foundation – Research grant recipient  
Cancer Council NSW – Research grant recipient  
National Health and Medical Research Council, Australia – Research grant recipient

**Roshini Abraham, PhD**

MAYO CLINIC  
Baxalta/Shire – Consultant receiving consulting fee

**Troy Torgerson, MD, PhD**

UNIVERSITY OF WASHINGTON AND SEATTLE  
CHILDREN'S RESEARCH INSTITUTE  
Baxalta/Shire – Consultant receiving consulting fee  
CSL Behring – Consultant receiving consulting fee  
ADMA – Consultant receiving consulting fee  
aTyr Pharmaceuticals – Consultant receiving consulting fee

**V. Koneti Rao, MD**

NATIONAL INSTITUTE OF ALLERGY AND  
INFECTIOUS DISEASES, NIH  
Novartis – Funds through CRADA – Sponsor of research project

**Vincent Bonagura, MD**

ALEXANDRA & STEVEN COHEN CHILDREN'S  
MEDICAL CENTER  
Baxalta/Shire – Advisory committee member receiving speaker fee  
Grifols – Advisory committee member receiving speaker fee

## SEATTLE VISITOR INFORMATION

### THINGS TO DO:

**Pike Place Market:** 110 year old farmers market with 35 restaurants, 11 bakeries, fish & produce vendors. Visit the gum wall and the fish stand where they throw the fish while you're there!

**Seattle Center:** This 74-acre park was originally built for the 1962 World's Fair. It now serves as a location for arts, entertainment & leisure activities. Visit the iconic Space Needle, the Museum of Pop, the Pacific Science Center and more!

**Pioneer Square:** Home of the great fire of 1889, and the birth place of UPS, THE UNDERGROUND TOUR, many art & glass galleries & our professional sports stadiums.

**Waterfront & Piers:** Catch spectacular views of Elliott Bay, eat at one of the many fresh seafood restaurants, buy all your Seattle souvenirs at one of the many souvenir & curio shops, take a scenic ferry ride or visit the Seattle aquarium, all available on the Seattle waterfront.

**International district (A.K.A., CHINA TOWN):** It isn't just a place to shop & play; it's a thriving community & neighborhood. Uwajimaya Asian groceries & gifts. Hing Hay Park, Wing Luke museum, the pinball machine museum, are just some of the many attractions here.

**Discovery Park:** A 534 acre park in the peninsular neighborhood Magnolia. 12 miles of walking trails, the United Indians of All Tribes Daybreak Cultural Center, a lighthouse, and the chance to view Pacific Northwest wildlife.

**Ballard:** A hip little town in the NW Seattle area settled in 1853... offering some of the best restaurants, pubs, shops, spas & parks. Shop & stroll Market St while you're there.

**Volunteer Park:** Located in the North Capitol Hill neighborhood, this densely populated residential district features a prominent nightlife & entertainment area. Many great restaurants and a large alternative & counter culture community exist here.

**Bainbridge Island:** Has Island charm, natural beauty, rural character, offering many parks and artisan wineries, unique stores & restaurants.

### PLACES TO EAT

**Relish Burger Bistro** (Located in The Westin)

*American*

Open for breakfast, lunch, and dinner

Relish Burger Bistro is a contemporary restaurant offering a modern twist on an American classic, combining Seattle's culinary influence with gourmet burgers at downtown Seattle's newest eatery.

**Barolo (0.05 mi)**

*Italian*

Open for lunch and dinner

Barolo Ristorante offers a mix of timeless, old-world northern Italian dishes crafted with a contemporary presentation, using quality natural and organic products and ingredients, many from the Pacific Northwest.

**Andaluca (0.07 mi)**

*Mediterranean*

Open for breakfast and dinner

Andaluca is a nationally recognized culinary oasis. Resonating with the romance of the Mediterranean, its food and design have been a winning combination since 1996.

**Assaggio (0.09 mi)**

*Italian*

Open for lunch and dinner

Italian cuisine in a space filled with Michelangelo-inspired artwork.

**Miller's Guild (0.09 mi)**

*American*

Open for breakfast, lunch, and dinner

Wood-fired New American fare & cask-aged cocktails in sleek, modern digs.

**Dahlia Lounge (0.1 mi)**

*Northwest*

Open lunch and dinner

Modern space serving Asian-infused Pacific Northwest cuisine & known for its coconut cream pie.

**Le Pichet (0.3 mi)**

*French*

Open for brunch, lunch & dinner

Le Pichet is a 32 seat restaurant specializing in the regional cuisine and wine of France.





## 2017 CIS ANNUAL MEETING SCHEDULE AT-A-GLANCE

THURSDAY, MARCH 23		
4:30pm – 6:00pm	Welcome from CIS President & Fellowship Awardee Presentations	Grand 1
6:00pm – 7:00pm	Robert A. Good Lecture Newborn Screening for PID – and Beyond <b>Lennart Hammarström, MD, PhD</b>	Grand 1
FRIDAY, MARCH 24		
8:00am – 9:30am	Plenary Session: Next Generation Genomics in This Generation	Grand 1
9:30am – 10:00am	Morning Break	Grand Foyer
10:00am – 11:00am	Guided Poster Sessions	Vashon I & II
11:00am – 12:30pm	Plenary Session: Immunological Lessons Learned from PIDs	Grand 1
12:30pm – 1:30pm	Lunch / Exhibit Hall Open	Grand 2 & 3 Foyer
1:30pm – 2:00pm	Poster Presentation Viewing / Exhibit Hall Open	Grand 2 & 3
2:00pm – 3:30pm	Plenary Session: The “Ome” and “Omics”	Grand 1
3:30pm – 4:00pm	Coffee Break	Grand Foyer
4:00pm – 5:00pm	The CIS Fahey/Rose Founders Lecture Translating Immunological Advances Into Solutions for Global Health Problems <b>Chris Wilson, MD</b>	Grand 1
5:00pm – 5:30pm	DAIT/NIAID Funding Opportunities for PID	Grand 1
5:30pm – 6:00pm	CIS Business Meeting & Award Presentations <i>Wine &amp; Cheese Reception to Follow</i>	Grand 1
6:00pm – 7:30pm	ECI Reception	Lobby Bar Loft
SATURDAY, MARCH 25		
8:00am – 9:30am	Plenary Session: Immune Regulation	Grand 1
9:30am – 10:00am	Coffee Break	Grand Foyer
10:00am – 11:00am	Guided Poster Sessions	Vashon I & II
11:00am – 12:30pm	Plenary Session: Hematopoietic Cell Transplantation and Immune Reconstitution	Grand 1
12:30pm – 1:30pm	Lunch / Exhibit Hall Open	Grand 2 & 3 Foyer
1:30pm – 2:00pm	Poster Presentation Viewing / Exhibit Hall Open	Grand 2 & 3
2:00pm – 3:30pm	Plenary Session: Tales From the Listserv	Grand 1
3:30pm – 4:00pm	Coffee Break	Grand Foyer
4:00pm – 4:20pm	Presidential Award Lecture <b>Charlotte Cunningham-Rundles, MD, PhD</b>	Grand 1
4:20pm – 5:00pm	Richard Schiff Lecture Combinatorial Approaches to Understand Autoimmune Risk: Mechanistic Insight from Immunodeficiency and GWAS <b>David Rawlings, MD</b>	Grand 1
5:00pm – 7:00pm	CIS Closing Reception	Grand 2 & 3
SUNDAY, MARCH 26		
8:00am – 10:00am	Plenary Session: Hot New Defects in Primary Immunodeficiencies!	Grand 1
10:00am – 10:15am	Coffee Break	Grand Foyer
10:15am – 12:15pm	Plenary Session: Clinical Management Conundrums in PIDs	Grand 1

## SCHEDULE OF EVENTS

### THURSDAY, MARCH 23

4:30 pm - 4:40 pm	<b>Welcome from CIS President</b> <b>Jordan Orange, MD, PhD</b> Baylor College of Medicine & Texas Children's Hospital	Grand Ballroom I
4:40 pm - 6:00 pm	<b>CIS Fellowship Grantee Presentations</b> 1.5 AMA PRA Category 1 Credits™ <i>Moderator:</i> <b>Jordan Orange, MD, PhD</b> , Baylor College of Medicine <i>Speakers:</i> Revealing the Role of Human IgA in Gut Homeostasis <b>Jared Silver, MD, PhD</b> , Brigham and Women's Hospital Using Persistent Cutaneous Viral Infections to Uncover Novel Immune Dysfunction <b>Sarah Henrickson, MD, PhD</b> , The Children's Hospital of Philadelphia <i>Oral Abstract</i> <i>SUCCESSFUL CLINICAL STUDY OF LENIOLISIB (CDZ173), A SMALL MOLECULE PI3K-DELTA INHIBITOR, IN PATIENTS WITH APDS/PASLI</i> <b>V. Koneti Rao, MD</b> , National Institute of Allergy and Infectious Diseases, NIH	Grand Ballroom I
6:00pm - 7:00pm	<b>Robert A. Good Lecture</b> <i>Sponsored by The Robert A. Good Society and The Jeffrey Modell Foundation</i> 1 AMA PRA Category 1 Credits™ <i>Moderator:</i> <b>Jordan Orange, MD, PhD</b> , Baylor College of Medicine <i>Speaker:</i> Newborn screening for PID - and Beyond <b>Lennart Hammarström, MD, PhD</b> , Karolinska Institutet	Grand Ballroom I
7:00pm - 8:30pm	<b>Corporate Sponsored Dinner Symposium</b> 1.5 AMA PRA Category 1 Credits <i>Navigating through the Diagnostic and Treatment Controversies in Specific Antibody Deficiency: US and European Perspectives and Recommendations</i> *Ticketed Event* <i>Sponsored by an Unrestricted Educational Grant from Shire</i>	Fifth Avenue Room

### FRIDAY, MARCH 24

7:00am - 8:00am	Continental Breakfast	Grand Foyer
8:00am - 9:30am	<b>Plenary Session: Next Generation Genomics in This Generation</b> 1.5 AMA PRA Category 1 Credits™ <i>Moderators:</i> <b>Roshini Sarah Abraham, PhD</b> , Mayo Clinic <b>Yuval Itan, PhD</b> , The Rockefeller University <i>Speakers:</i> Technologies Around Genomics <b>Brendan Lee, MD, PhD</b> , Baylor College of Medicine Understanding the Shared Genetic Architecture of Autoimmune and Inflammatory Disorders: Implications on Mechanism and Clinical Translation <b>Charlly Kao, PhD</b> , Children's Hospital of Philadelphia 21st Century Genomic Advances for Clinicians <b>Isabelle Meyts, MD, PhD</b> , University Hospitals Leuven <i>Oral Abstract</i> <i>NUCLEASE-TARGETED GENE-EDITING TO ACHIEVE STABLE FOXP3 EXPRESSION IN PRIMARY HUMAN T CELLS DELAYS THE ONSET XENOGENEIC MODEL OF GRAFT-VERSUS-HOST DISEASE (GVHD)</i> <b>Yufei Xiang, MD, PhD</b> , Seattle Children's Research Institute	Grand Ballroom I
9:30am - 10:00am	<b>Morning Break</b>	Grand Foyer

## SCHEDULE OF EVENTS

### FRIDAY, MARCH 24, CONTINUED

10:00am - 11:00am	<b>Guided Poster Session Group I</b> <i>Moderators:</i> <b>Jolan Walter, MD, PhD</b> , Johns Hopkins All Children's Hospital <b>Artemio Jongco, MPH, MD, PhD</b> , Feinstein Institute for Medical Research <i>COMBINED IMMUNODEFICIENCY AND EPSTEIN-BARR VIRUS-INDUCED B CELL MALIGNANCY IN HUMANS WITH INHERITED CD70 DEFICIENCY</i> <b>Huie Jing, PhD</b> , National Institute of Allergy and Infectious Diseases, NIH <i>EVALUATION OF TROUGH LEVELS OF ANTIBODIES TO 12 SEROTYPES OF S. PNEUMONIA IN A PHASE III CLINICAL TRIAL IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY (PID)</i> <b>Troy R. Torgerson, MD, PhD</b> , Seattle Children's Research Institute <i>HEMATOPOIETIC STEM CELL TRANSPLANTATION RESCUES THE VASCULAR, HAEMATOLOGICAL AND IMMUNOLOGICAL PHENOTYPE IN ADENOSINE DEAMINASE 2 DEFICIENCY</i> <b>Isabelle Meyts, MD, PhD</b> , University Hospitals Leuven <i>LONG TERM PROGNOSIS IN AUTOSOMAL DOMINANT HYPER IgE SYNDROME</i> <b>Amanda K. Urban, CRNP</b> , Leidos Biomedical Research <i>A MOUSE MODEL OF TYPE 1 KABUKI SYNDROME WITH DEFECTIVE HUMORAL RESPONSES TO MUCOSAL VACCINATION</i> <b>Tareian A. Cazares, MS</b> , Cincinnati Children's Hospital Medical Center	Vashon I
10:00am - 11:00am	<b>Guided Poster Session Group II</b> <i>Moderators:</i> <b>Lisa Kobrynski, MD, MPH</b> , Emory University <b>Jennifer Leiding, MD</b> , University of South Florida <i>EFFICACY OF THE JAK INHIBITOR RUXOLITINIB IN TWO PATIENTS WITH SAVI SYNDROME</i> <b>Stefano Volpi, MD, PhD</b> , Istituto Giannina Gaslini <i>MASS MINING: A CROWDSOURCING APPROACH FOR META-ANALYZING GENE EXPRESSION SIGNATURES OF AUTOIMMUNITY USING LARGE-SCALE PUBLIC DATA SETS</i> <b>Rachel Sparks, MD, MPH</b> , National Institute of Allergy and Infectious Diseases, NIH <i>SAFETY AND EFFICACY OF GENE THERAPY USING A MODIFIED SELF-INACTIVATING GAMMARETROVIRAL VECTOR FOR SCID-X1</i> <b>Sung-Yun Pai, MD</b> , Boston Children's Hospital <i>SIBLINGS WITH FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS TYPE 5 IN ASSOCIATION WITH SEVERE ENTEROPATHY: MANAGEMENT DILEMMAS</i> <b>Roxane Labrosse, MD</b> , CHU Sainte-Justine, University of Montreal <i>A LINEAR DISCRIMINANT MODEL TO PREDICT A CLINICAL DIAGNOSIS OF PRIMARY IMMUNODEFICIENCY</i> <b>Saul Oswaldo Lugo-Reyes, MD, MS</b> , National Institute of Pediatrics	Vashon II



## SCHEDULE OF EVENTS

### FRIDAY, MARCH 24, CONTINUED

11:00am - 12:30pm	<b>Plenary Session: Immunological Lessons Learned from PIDs</b> 1.5 AMA PRA Category 1 Credits™ <i>Moderators:</i> <b>Manish Butte, MD, PhD, UCLA</b> <b>Monica Lawrence, MD, University of Virginia</b> <i>Speakers:</i> B Cell Tolerance Mechanisms and Defects in PIDs <b>Neil Romberg, MD, University of Pennsylvania</b> Conventional T Cell Subsets <b>Stuart Tangye, PhD, Garvan Institute of Medical Research</b> Dendritic Cell Biology <b>Venetia Bigley, MB, BChir, PhD, MRCP, FRCPath, Newcastle University</b> <i>Oral Abstracts</i> MUTATIONS IN THE TYROSINE-PROTEIN KINASE LYN CAUSE AN EARLY-ONSET NEUTROPHILIC VASCULITIS SYNDROME <b>Adriana A. Jesus, MD, PhD, National Institutes of Health</b> MUTATIONS IN THE H <sup>+</sup> -ATPASE SUBUNIT ATP6V0A2 ASSOCIATED WITH CUTIS LAXA ALSO CAUSE NK CELL DEFICIENCY <b>Levi B. Watkin, PhD, Baylor College of Medicine</b>	Grand Ballroom I
12:30pm - 1:30pm	<b>Lunch / Exhibit Hall Open</b>	Grand Ballroom II & III, Foyer
1:30pm - 2:00pm	<b>Poster Presentation Viewing / Exhibit Hall Open</b>	Grand Ballroom II & III
2:00pm - 3:30pm	<b>Plenary Session: The “Ome” and “Omics”</b> 1.5 AMA PRA Category 1 Credits™ <i>Moderators:</i> <b>Sergio Rosenzweig, MD, PhD, National Institute of Allergy and Infectious Diseases, NIH</b> <b>Elena Hsieh, MD, University of Colorado, Denver</b> <i>Speakers:</i> Systems Genomics and Systems Immunology <b>John Tsang, PhD, National Institute of Allergy and Infectious Diseases, NIH</b> Transcriptome of Human Treg Subsets <b>Daniel Campell, PhD, Benaroya Research Institute</b> A New Genetic Etiology of Inherited NK Cell Deficiency <b>Emmanuelle Jouanguy, PhD, INSERM / Université Paris Descartes</b> <i>Oral Abstract:</i> DRIED BLOOD SPOTS FOR GENE SEQUENCING: TRAVELLING ON LOW BUDGET! <b>Gesmar Segundo, MD, PhD, Seattle Children's Research Institute, Federal University of Uberlandia</b>	Grand Ballroom I
3:30pm - 4:00pm	<b>Afternoon Break</b>	Grand Foyer
4:00pm - 5:00pm	<b>The CIS Fahey/Rose Founders Lecture</b> 1 AMA PRA Category 1 Credits™ <i>Moderators:</i> <b>Joyce Yu, MD, Morgan Stanley Children's Hospital/Columbia University Medical Center</b> <b>Hans Ochs, MD, University of Washington</b> <i>Speaker:</i> Translating Immunological Advances Into Solutions for Global Health Problems <b>Christopher Wilson, MD</b>	Grand Ballroom I
5:00pm - 5:30pm	<b>Plenary Session: DAIT/NIAID Funding Opportunities for PID</b> .5 AMA PRA Category 1 Credits™ <b>Frosso Voulgaropoulou, PhD, National Institute of Allergy and Infectious Diseases, NIH</b>	Grand Ballroom I
5:30pm - 6:00pm	<b>CIS Business Meeting &amp; Award Presentations</b> <i>Wine &amp; Cheese Reception to Follow</i>	Grand Ballroom I
6:00pm - 7:30pm	<b>Early Career Immunologists (ECI) Reception</b>	Lobby Bar Loft

## SCHEDULE OF EVENTS

### SATURDAY, MARCH 25

7:00am - 8:00am	<b>Continental Breakfast</b>	Grand Foyer
8:00am - 9:30am	<b>Plenary Session: Immune Regulation</b> 1.5 AMA PRA Category 1 Credits™ Moderators: <b>Thomas Fleisher, MD</b> , NIH Clinical Center <b>Joud Hajjar, MD</b> , Baylor College of Medicine Speakers: Formation of Immunological Memory in Complex Infections <b>Marion Pepper, PhD</b> , University of Washington The Deficiency of Adenosine Deaminase 2--A Master of Disguise <b>Amanda Ombrello, MD</b> , NHGRI, NIH Manipulating Regulatory T Cells to Restore Tolerance <b>Talal Chatila, MD</b> , Boston's Children Hospital Oral Abstracts VERY EARLY ONSET IBD- THE SEARCH FOR MONOGENIC CAUSES <b>Kathleen Sullivan, MD, PhD</b> , Children's Hospital of Philadelphia AN INHERITED SYNDROME OF AUTOIMMUNITY ASSOCIATED WITH CD40LG DUPLICATION <b>Carole Le Coz, PhD</b> , Children's Hospital of Philadelphia	Grand Ballroom I
9:30am - 10:00am	<b>Morning Break</b>	Grand Foyer
10:00am - 11:00am	<b>Guided Poster Session Group I</b> Moderators: <b>Jack Bleesing, MD, PhD</b> , Cincinnati Children's Hospital <b>Zeynep Yesim Kucuk, MD</b> , Cincinnati Children's Hospital LIVER ABNORMALITIES IN DOCK8 DEFICIENCY <b>Anahita Agharahimi, CRNP</b> , National Institute of Allergy and Infectious Diseases, NIH HUMAN CD40L DEFICIENCY DYSREGULATES THE MACROPHAGE TRANSCRIPTOME CAUSING FUNCTIONAL DEFECTS THAT ARE IMPROVED BY EXOGENOUS IFN-γ <b>Antonio Condino-Neto, MD, PhD</b> , University of Sao Paulo PATIENTS WITH XIAP DEFICIENCY HAVE CIRCULATING FREE IL-18 WHICH MAY REPRESENT A THERAPEUTIC TARGET <b>Rebecca Marsh, MD</b> , Cincinnati Children's Hospital Medical Center REDUCED TOXICITY ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WITH BUSULFAN, FLUDARABINE AND ALEMTUZUMAB: A PROMISING APPROACH FOR PRIMARY IMMUNE DEFICIENCIES REQUIRING MYELOABLATIVE HCT? <b>Sharat Chandra, MD, MRCPCH</b> , Cincinnati Children's Hospital Medical Center CHROMIUM RELEASE NATURAL KILLER CELL CYTOTOXICITY HAS POOR DIAGNOSTIC ACCURACY COMPARED TO FLOW CYTOMETRIC PERFORIN AND CD107a TESTING FOR DETECTION OF PATIENTS WITH FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS <b>Tamar S. Rubin, MD</b> , University of Alberta	Vashon I

## SCHEDULE OF EVENTS

### SATURDAY, MARCH 25, CONTINUED

10:00am – 11:00am	<b>Guided Poster Session Group II</b> <i>Moderators:</i> <b>Megan A. Cooper, MD</b> , Washington University in St. Louis <b>David Hagin, MD, PhD</b> , Tel-Aviv Sourasky Medical Center <i>VEDOLIZUMAB IN CHRONIC GRANULOMATOUS DISEASE: A SAFE AND PROMISING BRIDGE THERAPY FOR CGD RELATED COLITIS</i> <b>Christa S. Zerbe, MD</b> , National Institute of Allergy and Infectious Diseases, NIH <i>GERMLINE HYPOMORPHIC, DOMINANT NEGATIVE CARD11 MUTATIONS IN SEVERE ATOPIC DISEASE.</i> <b>Andrew L. Snow, PhD</b> , Uniformed Services University of the Health Sciences <i>SEVERE COMBINED IMMUNODEFICIENCY CAUSED BY THYMIC APLASIA DUE TO FAMILIAL MUTATION IN TBX1</i> <b>David S. Lindsay, MD</b> , University of South Florida <i>VILLOUS ATROPHY IS THE HALLMARK OF LONG TERM SURVIVAL IN CHRONIC NOROVIRUS INFECTION</i> <b>Avni Y. Joshi, MD, MS</b> , Mayo Clinic <i>ROLE OF GUT MICROBIOTA TO MONITOR IMMUNE DYSREGULATION IN CONGENITAL IMMUNE DYSREGULATION SYNDROMES</i> <b>Eleonora Gambinieri, MD</b> , University of Florence, Department of Sciences for Woman and Child's Health "Anna Meyer" Children's Hospital	Vashon II
11:00am – 12:30pm	<b>Plenary Session: Hematopoietic Cell Transplantation and Immune Reconstitution</b> 1.5 AMA PRA Category 1 Credits™ <i>Moderators:</i> <b>Shanmuganathan Chandrakasan, MD</b> , Emory University School of Medicine, Children's Healthcare of Atlanta <b>László Maródi, MD</b> , Semmelweis University <i>Speakers:</i> New Approaches to Hematopoietic Cell Transplantation <b>Brenda Sandmaier, MD</b> , Fred Hutchinson Cancer Research Center Immune Reconstitution in Hematopoietic Cell Transplantation <b>Jan Storek, MD, PhD</b> , University of Calgary Hematopoietic Cell Transplantation for PIDs: The Indian Experience <b>Revathi Raj, MD</b> , Apollo Hospitals Hematopoietic Transplantation: Thinking Outside the Box <b>Andrew Cant, BSc, MD, FRCP, FRCPC</b> Newcastle General Hospital <i>Oral Abstract</i> <i>WISKOTT-ALDRICH SYNDROME: AN INTERNATIONAL STUDY ANALYZING THE IMPACT OF TREATMENT DECISIONS ON FREQUENCY OF DISEASE-RELATED COMPLICATIONS AND PHYSICIAN-PERCEIVED QUALITY OF LIFE</i> <b>Michael H Albert, MD</b> , Dr. von Hauner University Children's Hospital	Grand Ballroom I
12:30pm – 1:30pm	<b>Lunch / Exhibit Hall Open</b>	Grand Ballroom II & III, Foyer
1:30pm – 2:00pm	<b>Poster Presentation Viewing / Exhibit Hall Open</b>	Grand Ballroom II & III,



## SCHEDULE OF EVENTS

### SATURDAY, MARCH 25, CONTINUED


2:00pm - 3:30pm	<b>Plenary Session: Tales from the Listserv</b> 1.5 AMA PRA Category 1 Credits™ Moderators: <b>Elie Haddad, MD, PhD</b> , CHU Ste-Justine, University of Montreal <b>Mikko Seppänen, MD, PhD</b> , Helsinki University Central Hospital <b>Eric Allenspach, MD, PhD</b> , Seattle Children's Hospital Mystery Case #1 <b>Megan A. Cooper, MD</b> , Washington University in St. Louis Mystery Case #2 <b>Benjamin Wright, MD</b> , Mayo Clinic Mystery Case #3 <b>Luis Ignacio Gonzalez-Granado, MD</b> , Hospital Universitario Doce de Octubre	Grand Ballroom I
3:30pm – 4:00pm	<b>Afternoon Break</b>	Grand Foyer
4:00pm – 4:20pm	<b>Plenary Session: Presidential Award Lecture</b> .25 AMA PRA Category 1 Credits™ Speaker: <b>Charlotte Cunningham-Rundles, MD, PhD</b> , Mt. Sinai Medical School	Grand Ballroom I
4:20pm - 5:00pm	<b>Richard Schiff Lecture</b> .75 AMA PRA Category 1 Credits™ Moderators: <b>Antonio Condino-Neto, MD, PhD</b> , University of Sao Paulo <b>Andrew L. Snow, PhD</b> , Uniformed Services University of the Health Sciences Speaker: Combinatorial Approaches to Understand Autoimmune Risk: Mechanistic Insight From Immunodeficiency and GWAS <b>David Rawlings, MD</b> , Seattle Children's Research Institute Supported by an unrestricted educational grant from Baxalta	Grand Ballroom I
5:00pm - 7:00pm	<b>CIS Closing Reception</b>	Grand Ballroom II & III,

## SCHEDULE OF EVENTS

### SUNDAY, MARCH 26

7:00am - 8:00am	<b>Continental Breakfast</b>	Grand Foyer
8:00am - 10:00am	<p><b>Plenary Session: Hot New Defects in Primary Immunodeficiencies</b>  2 AMA PRA Category 1 Credits™</p> <p><i>Moderators:</i>  <b>Maite de la Morena, MD</b>, University of Texas Southwestern  <b>Lisa Forbes, MD</b>, Baylor College of Medicine</p> <p><i>Speakers:</i>  A New Syndromic Defect Associated with Thymic Dysfunction and SCID  <b>Luigi Notarangelo, MD</b>, National Institute of Allergy and Infectious Diseases, NIH  New Genetic NKD  <b>Jordan Orange, MD, PhD</b>, Baylor College of Medicine  Hoffman Syndrome--New Immunodeficiency Defect  <b>Lori Broderick, MD, PhD</b>, University of California, San Diego  Human MDA5 deficiency confers susceptibility to human rhinovirus infections  <b>Helen Su, MD, PhD</b>, National Institute of Allergy and Infectious Diseases, NIH  Inherited Human ZNF341 Deficiency Underlies Candidiasis and Allergy  <b>Anne Puel, PhD</b>, INSERM/Université Paris Descartes-Sorbonne Paris Cité</p> <p><i>Oral Abstracts</i>  RPSA MUTATIONS IN ISOLATED CONGENITAL ASPLENIA (ICA): A RIBOSOMOPATHY UNVEILED  <b>Barbara Bosch, MD</b>, The Rockefeller University  THE ZINC-FINGER-TRANSCRIPTION-FACTOR ZNF341 DEFICIENCY IN 3 SISTERS  <b>Sara Sebnem Kilic, MD</b>, Uludağ University Medical Faculty</p>	Grand Ballroom I
10:00am - 10:15am	<b>Coffee Break</b>	Grand Foyer
10:15am - 12:15pm	<p><b>Plenary Session: Clinical Management Conundrums in PIDs</b>  2 AMA PRA Category 1 Credits™</p> <p><i>Moderators:</i>  <b>Steven Holland, MD</b>, National Institute of Allergy and Infectious Diseases, NIH  <b>Nicholas Rider, DO</b>, Texas Children's Hospital</p> <p><i>Speakers:</i>  Hematopoietic Cell Transplantation for PIDs  <b>Lauri Burroughs, MD</b>, Fred Hutchinson Cancer Research Center &amp; University of Washington  Autoimmune Cytopenias in PIDs  <b>Markus Seidel, MD</b>, Medical University of Graz  Cytokine Release Syndrome  <b>Michael Jensen, MD</b>, University of Washington School of Medicine &amp; Seattle Children's Research Institute  IBD in PIDs  <b>Troy Torgerson, MD, PhD</b>, University of Washington &amp; Seattle Children's Research Institute  Respiratory Papillomatosis  <b>Vincent Bonagura, MD</b>, Alexandra &amp; Steven Cohen Children's Medical Center</p>	Grand Ballroom I

EXHIBIT HALL FLOOR PLAN





## EXHIBITOR AND SPONSOR DESCRIPTIONS

### BOOTH 104

#### **Accredo Specialty Pharmacy**

Accredo is a full-service specialty pharmacy dedicated to caring for people with rare and complex conditions. We deliver specialized pharmacy services and therapy management programs through specialty-trained pharmacists, nurses, reimbursement specialists and patient care representatives. We're committed to proactively supporting patients, their families and providers, and making medicine more affordable.

To learn more about our service, call 866.820.IVIG (4844) or visit [accredo.com](http://accredo.com).

### BOOTH 402

#### **ADMA Biologics**

ADMA is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the proposed treatment of Immune Deficiencies and the prevention and treatment of certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. ADMA has received U.S. Patent 9,107,906 relating to certain aspects of its product candidate. For more information, please visit [www.admabiologics.com](http://www.admabiologics.com).

### BOOTH 302

#### **Axela Care**

AxelaCare, a BrivoRx Infusion Services company, is a national home infusion provider with more than 30 pharmacy locations across the country, and an extensive team of employed clinicians. Services include immunoglobulin, anti-infectives, inotropes, parenteral nutrition and other specialty infusions. AxelaCare is a leader in innovation, including our Special Assistance Unit (SAU) for complex clinical and insurance issues, and CareExchange technology for wireless collection of patient outcomes for therapy optimization. Joint Commission and URAC certified, AxelaCare has extensive local, regional, and national payer contracts to facilitate an easy referral process to ensure excellent care for your patients.

### BOOTH 303

#### **Beckman Coulter Life Sciences**

Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing. More than 275,000 Beckman Coulter systems operate in both Diagnostics and Life Sciences laboratories on seven continents. For over 75 years, our products have been making a difference

in peoples' lives by improving the productivity of medical professionals and scientists, supplying critical information for improving patient health and delivering trusted solutions for research and discovery. From basic cellular analysis to advanced cell sorting methods and flow cytometry applications count on Beckman Coulter for efficient and reliable solutions to today's research challenges.

### BOOTH 203

#### **The Binding Site**

Binding Site is committed to developing special protein assays and automated systems for the improvement of patient care. The market leader in immunodiagnostics for Immunodeficiency, Binding Site assays measure specific antibody response to vaccinations and quantify immunoglobulins, IgG and IgA subclasses. Run on the Optilite® analyzer, the future of special protein testing, our wide menu of assays includes Freelite® for the diagnosis and monitoring of myeloma. With our extensive development expertise, patented antibody production technology, and medical educators, backed by clinical practice guidelines, Binding Site provides healthcare professionals with tools to significantly improve diagnosis and management of patients. [www.bindingsite.com](http://www.bindingsite.com)

### BOOTH 300

#### **Bio Products**

Bio Products Laboratory (BPL) is a global company with 60 years of history in plasma research, technology, and manufacturing. Originally part of the world-famous Lister Institute, BPL has a full line of products derived from plasma collected at 35 company-owned collection centers across the US. For more information please visit [www.bpl-us.com](http://www.bpl-us.com).

### BOOTH 307

#### **Coram CVS Specialty Infusion Services**

CVS Specialty and Coram provide compassionate, high-quality infusion care to patients where they live, work or travel. With nearly 1,200 skilled clinicians, more than 90 locations and 70 local infusion suites, and more than 30 years of experience, Coram CVS Specialty Infusion Services provides access to 99.9 percent of all infused drugs, including immunoglobulins, and those for alpha-1 and MS.

On-site Clinical Service Liaisons provide complete discharge-to-home coordination. All patients receive individualized care, support, training, and easy-to-use instruction materials. Leading with commitment from the heart, the company has achieved a 96 percent patient satisfaction rating for seven years.

### BOOTH 100

#### **CSL Behring**

CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients' needs using the latest technologies to develop and deliver innovative therapies. The company offers the broadest range of products in the industry for treating primary immune deficiencies, coagulation disorders, hereditary angioedema, inherited respiratory disease, and neurological disorders. CSL Behring's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn. The company operates one of the world's largest plasma collection networks. For more information visit [www.cslbehring.com](http://www.cslbehring.com) and follow us on [www.Twitter.com/CSLBehring](https://twitter.com/CSLBehring).

### BOOTH 202

#### **EMED Technologies**

EMED Technologies develops, manufactures and markets the SClg60™ Infusion System. This unique sub-q infusion system is the only mechanical syringe pump system cleared by FDA for use with subcutaneous immunoglobulin Hizentra, Gammagard and Shire's new Cuvitru. The system features Soft-Glide® needle sets, patented VersaRate® and Versarate Plus® adjustable flow rate control sets and a flow rate calculator which can be accessed at [www.versarate.com](http://www.versarate.com).

### BOOTH 409

#### **GeneDX**

### BOOTH 200

#### **Grifols USA, LLC**

Grifols is a global healthcare company whose mission is to improve the health and well-being of people around the world. We have three primary divisions – Bioscience, Diagnostic and Hospital – that develop, produce and market our innovative products and services to medical professionals in more than 100 countries around the world.

### BOOTH 405

#### **Horizon Pharma**

Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit: <http://www.horizonpharma.com/>

## EXHIBITOR LISTING

### BOOTH 400

#### **Immune Deficiency Foundation**

The Immune Deficiency Foundation (IDF) is the national non-profit patient organization dedicated to improving the diagnosis, treatment and quality of life of persons with primary immunodeficiency diseases through advocacy, education and research.

### BOOTH 106

#### **Immunoglobulin National Society**

Immunoglobulin National Society (IgNS) is the leading professional organization dedicated to the advancement of Ig Therapy practice across healthcare professional disciplines, areas of practice, and treatment settings. IgNS offers robust educational programs for nurses, pharmacists, and physicians; Ig Therapy Standards of Practice; and Certification. Visit us at [www.ig-an.org](http://www.ig-an.org). Save the date for the IgNS 6th National Conference on October 5-8, 2017.

### BOOTH 403

#### **Kroger Specialty Infusion**

Kroger Specialty Infusion is a specialized provider of IgG therapy. Our unique service model includes pharmacy expertise that includes review and monitoring of patient outcomes and a unique wellness approach to Ig therapy. We possess a national network of infusion nurses specifically trained in IgG administration. Our streamlined care coordination includes superior reimbursement services and a high touch patient advocacy program tailored to the individualized needs of IgG patients and their caregivers.

### BOOTH 201

#### **Leadiant Biosciences, Inc.**

Leadiant Biosciences, Inc. is a rare corporation dedicated to creating novel medicines for the unmet needs of patients with rare diseases. Truly unique in its field, Leadiant Biosciences places its considerable scientific resources behind the discovery of compounds that benefit the few. Simply because it's the right thing to do. By maintaining an environment based on integrity, commitment, and placing the patient first, Leadiant Biosciences is able to consider what may be a small commercial success nothing less than a human triumph.

### BOOTH 401

#### **Medical College of Wisconsin**

The Clinical Immunodiagnostic and Research Laboratory (CIRL) and Allergy Immunology Diagnostic Lab Center (AIDLC), at MCW, perform comprehensive testing for the diagnosis of primary immunodeficiencies (PIDs) and allergic disorders. The CIRL performs flow cytometric-based assays for the detection of PIDs. The AIDLC performs serologic assays for the diagnosis of hypersensitivity pneumonitis, allergic

bronchopulmonary aspergillosis and latex allergy. The AIDLC also performs a Salmonella Typhi IgG assay to quantitate specific antibody responses to the killed polysaccharide S. typhi vaccine.

### BOOTH 101

#### **National Jewish Health**

National Jewish Health Advanced Diagnostic Laboratories is a CAP, CLIA and CAP15189SM laboratory with unparalleled expertise developing immunological tests for immune deficiency and immune dysregulation - including comprehensive analysis of the complement system as well as the innate and adaptive immune systems, beryllium exposure, evaluation of hypersensitivity to nickel, cobalt and chromium metals in the context of joint implant failure, testing for infectious disease and molecular diagnostic tests. We have decades of experience in diagnostic testing in respiratory disease, immune deficiency, allergy and autoimmunity. Through collaborations with our world-renowned physicians and laboratory scientists, we develop high-quality laboratory tests and new therapies that transform lives.

### BOOTH 301

#### **Novartis**

Novartis Pharmaceuticals Corporation is dedicated to discovering, developing, manufacturing and marketing prescription drugs that help meet our customers' medical needs and improve their quality of life. For more information please visit our exhibit.

### NOT EXHIBITING

#### **Seattle Children's Research Institute**

Ranked as one of the top five children's hospitals by U.S. News & World Report, Seattle Children's serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho. Seattle Children's Research Institute is internationally recognized for its work in immunology and gene therapy through its Program in Cell and Gene Therapy (PCGT). The PCGT is developing curative therapies for children with inherited diseases of the blood and immune system. It is actively implementing gene replacement clinical trials and, in parallel, developing novel gene editing approaches for these disorders and for restoring tolerance in autoimmunity and transplantation. More information: [www.seattlechildrens.org/research](http://www.seattlechildrens.org/research)

### BOOTH 406

#### **Shire – Commercial**

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage

Disorders, Gastrointestinal/Internal Medicine/Endocrine and Hereditary Angioedema; and a growing franchise in Oncology. Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

### BOOTH 103

#### **Shire – Medical Affairs**

The Shire Medical Affairs booth will be staffed by Shire Medical Affairs representatives who are able to answer medical and scientific questions about Shire's immune globulin products. For more information on the Immunology therapeutic area, please visit [www.shire.com](http://www.shire.com)

## POSTER LISTING

Poster	Poster Title	Name	Affiliation
1	A NOVEL MUTATION IN THE SAND DOMAIN OF AIRE EXPLAINS THE HIDDEN RISK IN A PATIENT WITH TYPE I DIABETES MELLITUS	Jordan K. Abbott	National Jewish Health
2	MYELOSUPPRESSION EFFECT OF TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS IN PRIMARY IMMUNE DEFICIENCY DISEASE PATIENTS	Mehdi Adeli	Hamad Medical Corporation
3	NOVEL FAMILIAL NK CELL IMMUNODEFICIENCY REVEALED BY MASS CYTOMETRY AND WHOLE EXOME SEQUENCING	Joshua Alinger	Washington University in St Louis
4	COMPOUND HETEROZYGOUS RTEL1 MUTATIONS IN A CHILD WITH NEUTROPENIA, LYMPHADENITIS, RECURRENT INFECTIONS, AND DECREASED NK CELL FUNCTION.	Aba Al-Kaabi	Baylor College of Medicine
5	CLINICAL, IMMUNOLOGICAL AND MOLECULAR CHARACTERIZATION OF 93 PATIENTS WITH MAJOR HISTOCOMPATIBILITY CLASS II DEFICIENCY: A SINGLE CENTRE EXPERIENCE	Hamoud Al-Mousa	King Faisal Specialist Hospital & Research Center
6	A RARE CASE OF IDIOPATHIC CD4 LYMPHOCYTOPENIA WITH ACUTE RESPIRATORY FAILURE	Afia Babar	The Wright Center for Graduate Medical Education
7	RETROSPECTIVE ANALYSIS OF THE IMPORTANCE OF IMMUNOLOGIC EVALUATION IN PATIENTS RECEIVING RITUXIMAB AND CLINICAL IMPLICATIONS	Sara Barmettler	Massachusetts General Hospital
8	FUNCTIONAL DIAGNOSIS OF ATAXIA TELANGIECTASIA IN A FEMALE INFANT IDENTIFIED VIA NEWBORN SCREENING FOR SCID (NBS SCID)	Sara Barmettler	Massachusetts General Hospital
9	IDENTIFICATION OF T-CELL RECEPTOR CLONOTYPES IMPORTANT IN THE PATHOGENESIS OF COMMON VARIABLE IMMUNODEFICIENCY (CVID)	Sara Barmettler	Massachusetts General Hospital
10	T CELL LYMPHOPENIA WITH JAK3 MUTATIONS ASSOCIATED WITH DECREASED SIGNALING THROUGH THE IL-7 RECEPTOR	Jenna R.E. Bergerson	Ann and Robert H. Lurie Children's Hospital of Chicago
11	TREATMENT SATISFACTION DURING CLINICAL TRIALS WITH THE NEW HUMAN SUBCUTANEOUS IMMUNOGLOBULIN (SCIG 20%) IN PATIENTS WITH PIDD IN EUROPE (EU) AND NORTH AMERICA (NA) WHO WERE PREVIOUSLY TREATED WITH IVIG	Todd Berner	Shire
12	TREATMENT PREFERENCE ON THE NEW SUBCUTANEOUS IMMUNOGLOBULIN 20% (SCIG 20%) TREATMENT IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) IN EUROPE (EU)	Todd Berner	Shire
13	COMPLEX IMMUNE COMPLEXES - A RARE CASE OF XLA AND MPGN	Annaliesse Blincoe	CHU Sainte-Justine, University of Montreal
14	INCREASED MEMORY B CELLS – AN UNEXPECTED FINDING IN A PATIENT WITH A SPLICE SITE MUTATION IN PIK3R1 RESPONSIBLE FOR HYPER-IgM SYNDROME	Annaliesse Blincoe	CHU Sainte-Justine, University of Montreal
15	A NEW CASE OF X-LINKED PIGMENTARY RETICULATE DISORDER LINKED TO A RECURRENT MUTATION IN POLA1	Arturo Borzutzky	Pontificia Universidad Católica de Chile
16	PRIMARY INTESTINAL LYMPHANGIECTASIA (WALDMANN'S DISEASE) MIMICKING COMMON VARIABLE IMMUNODEFICIENCY	Arturo Borzutzky	Pontificia Universidad Católica de Chile
17	CHRONIC MUCOCUTANEOUS CANDIDIASIS DUE TO LIFR DEFICIENCY (STÜVE-WIEDEMANN SYNDROME)	Arturo Borzutzky	Pontificia Universidad Católica de Chile
18	Th17 IMPAIRMENT IN A PATIENT WITH ACTIVATED PHOSPHOINOSITIDE-3-KINASE-Δ SYNDROME (APSD) AND SALMONELLA SEPSIS.	Giorgia Bucciol	University of Padova; KU Leuven
19	RECURRENT SEVERE RESPIRATORY INFECTIONS DUE TO PATHOGENIC VARIANT IN TECPR2	Roxanne C. Oriel	Hofstra Northwell School of Medicine

## POSTER LISTING

Poster	Poster Title	Name	Affiliation
20	CVID WITH RENAL INTERSTITIAL INFLAMMATORY INFILTRATE OF CD 3+ CD8+ T CELLS	Jason W Caldwell	Wake Forest University School of Medicine
21	16q24 DUPLICATION AND IVE MARK SYNDROME: A NOVEL GENOMIC CAUSE?	Magda Carneiro-Sampaio	University of Sao Paulo
22	HYPERCOAGULABLE STATE IN CHRONIC GRANULOMATOUS DISEASE (CGD)	Johana B Castro-Wagner	University of South Florida
23	SEVERE COMBINED IMMUNE DEFICIENCY (SCID): NEED FOR UNIVERSAL NEWBORN SCREENING (NBS) IN PENNSYLVANIA (PA)	Hey Chong	Children's Hospital of Pittsburgh
24	A NOVEL CAUSE OF LYMPHOPENIA AND PRIMARY IMMUNODEFICIENCY ASSOCIATED WITH GERMLINE-ENCODED LOSS-OF-FUNCTION VARIANTS IN SGPL1	Megan A. Cooper	Washington University in St. Louis
25	MHV68 INFECTION IN A NOVEL rag2F62L/F62L MOUSE MODEL BASED ON A PATIENT WITH CID-AI/G PHENOTYPE	Krisztian Csomos	University of South Florida
26	SAFETY AND EFFECTIVENESS OF CONTINUOUS PROPHYLAXIS WITH AZITHROMYCIN FOR AUTOSOMAL DOMINANT HYPER-IgE SYNDROME (AD-HIES) PATIENTS: A 5-YEARS FOLLOW-UP	Jose Marcos Cunha	Federal University of Rio de Janeiro
27	A NOVEL MUTATION IN RIT1 GENE CAUSING NOONAN SYNDROME TYPE 8: MANAGEMENT OF HYPOGAMMAGLOBULINEMIA AND SEVERE ANEMIA ASSOCIATED WITH EXTENSIVE GASTROINTESTINAL LYMPHANGIECTASIA	Jose Marcos Cunha	Federal University of Rio de Janeiro
28	COMBINED IMMUNODEFICIENCY IN A BOY WITH MILLER-DIEKER SYNDROME.	Yesim Demirdag	Columbia University Medical Center, New York Presbyterian Hospital
29	ANTI-POLYSACCHARIDE ANTIBODIES AGAINST PNEUMOCOCCAL SEROTYPES IN PATIENTS WITH RECURRENT INFECTIONS	Victoria R Dimitriades	University of California Davis Medical Center
30	GLILD (GRANULOMATOUS LYMPHOCYTIC INTERSTITIAL LUNG DISEASE) TREATMENT IN A PEDIATRIC PATIENT WITH CTLA4 DEFICIENCY: CASE REPORT	Mayra Dorna	Universidade de Sao Paulo
31	INITIATION OF 20% SUBCUTANEOUS IMMUNOGLOBULIN THERAPY IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY NAÏVE TO IG THERAPY	Carla Duff	University of South Florida
32	IMMUNOMODULATORY EFFECTS OF RAPAMYCIN IN XENOGENEIC GRAFT VERSUS HOST DISEASE	Grégory Ehx	University of Liege
33	BROADENING OUR UNDERSTANDING OF THE NONINFECTIOUS DISEASE COMPLICATIONS OF CVID WITHIN THE UNITED STATES.	Jocelyn Farmer	Massachusetts General Hospital
34	SHIFTING OF INTRAVENOUS GAMMAGLOBULIN REPLACEMENT TO SUBCUTANEOUS ROUTE: A NEW APPROACH IN BRAZIL.	Natasha R Ferraroni	UnICEUB
35	EXPLORING THE CLINICAL AND IMMUNOLOGICAL DIFFERENCES BETWEEN COMMON VARIABLE IMMUNODEFICIENCY (CVID) AND IgG DEFICIENCY	Charles A. Filion	Icahn School of Medicine at Mount Sinai
36	HYPER IgD SYNDROME (HIDS) PRESENTING AS ARTHRITIS WITHOUT FEVER	Joel Louis Gallagher	Medical College of Wisconsin
37	PREVALENCE AND TREATMENT OF MONOGENIC CAUSES OF GRANULOMATOUS AND LYMPHOCYTIC INTERSTITIAL LUNG DISEASE (GLILD) IN PATIENTS PREVIOUSLY DIAGNOSED WITH CVID	Joel Louis Gallagher	Medical College of Wisconsin
38	SEVERE AUTO-IMMUNE ENTEROPATHY IN A PATIENT WITH A LOSS OF FUNCTION MUTATION IN TUMOR NECROSIS FACTOR ALPHA-INDUCED PROTEIN 3 (TNFAIP3/A20)	Yael Gernez	Icahn School of Medicine at Mount Sinai
39	VARIABLE PRESENTATION OF CHROMOSOMAL INSTABILITY SYNDROMES	Mirinda Gillespie	Johns Hopkins All Children's Hospital

## POSTER LISTING

Poster	Poster Title	Name	Affiliation
40	RAPIDLY EROSIIVE ARTHRITIS IN IPEX SYNDROME AFTER BONE MARROW TRANSPLANT	Miriah C Gillispie	Baylor College of Medicine/Texas Children's Hospital
41	THE DISTINCT PHENOTYPE AND FUNCTION OF CONVENTIONAL NK CELLS IN THE PERIPHERAL BLOOD AND TERMINAL ILEUM OF CROHN'S DISEASE PATIENTS	Sarah Glover	University of Florida
42	SUCCESSFUL TREATMENT OF MULTIPLE BRAIN ABSCESES CAUSED BY TRICHOSPORON INKIN IN A PATIENT WITH X-LINKED CHRONIC GRANULOMATOUS DISEASE (CGD)	Joud Hajjar	Baylor College of Medicine
43	REPORT OF A NOVEL FOXP3 VARIANT ASSOCIATED WITH RENAL FAILURE AND IMMUNE DYSREGULATION	Gretchen Harmon	Thomas Jefferson University Hospital & Nemours A.I. duPont Hospital for Children
44	FAMILIAL ALPS WITH VARIABLE PRESENTATIONS	Donna S. Hummell	Vanderbilt University (Vanderbilt Children's Hospital)
45	VARIABILITY OF PRIMARY IMMUNODEFICIENCY AND PROGRESSION TO CVID: A CASE REPORT	Tracy A Hwangpo	University of Alabama at Birmingham
46	PERSISTENT HYPOGAMMAGLOBULINEMIA AFTER TREATMENT WITH RITUXIMAB AND BORTEZOMIB FOR AUTOIMMUNE HEMOLYTIC ANEMIA	Melissa Iammatteo	Montefiore Medical Center/Albert Einstein College of Medicine
47	DIAGNOSTIC RATES OF GENETIC PANELS IN A LARGE SCID COHORT	Jane Juusola	GeneDx
48	HYPOGAMMAGLOBULINEMIA AFTER RITUXIMAB TREATMENT IN PEDIATRIC PATIENTS WITH AUTOIMMUNE CNS DISEASES	Amer M Khojah	Ann & Robert H. Lurie Children's Hospital of Chicago
49	AUTOSOMAL-RECESSIVE STAT-3-LIKE HYPER-IgE SYNDROME CAUSED BY A HOMOZYGOUS MUTATION IN A ZINC FINGER TRANSCRIPTION FACTOR	Sara Sebnem Kilic	Uludag University
50	A NEW LIQUID 10% INTRAVENOUS IMMUNOGLOBULIN (IVIG) ADMINISTERED WITH 15-MINUTE TITRATION PERIODS ALLOWS SHORTER INFUSION DURATIONS AND TOLERABILITY SIMILAR TO A 5% FORMULATION	Gary I. Kleiner	University of Miami Miller School of Medicine
51	NEWBORN SCREENING FOR SEVERE COMBINED IMMUNODEFICIENCY (SCID) IN GEORGIA: FALSE POSITIVES ON REPEAT TESTING	Lisa Kobrynski	Emory University
52	THE USE OF PIOGLITAZONE AS THERAPEUTIC APPROACH IN CHRONIC GRANULOMATOUS DISEASE: A SINGLE CASE EXPERIENCE	Patroula Koletsi	Great Ormond Street Hospital
53	ITRACONAZOLE PROPHYLAXIS THERAPEUTIC DRUG MONITORING (TDM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY (PID)	Patroula Koletsi	Great Ormond Street Hospital
54	IMPORTANCE OF GENETIC CONFIRMATION IN THE DIAGNOSIS OF CHRONIC GRANULOMATOUS DISEASE	Samantha A Kreuzburg	NIAID/NIH
55	ANALYSIS OF NCF1 IN PATIENTS WITH p47phox DEFICIENT CHRONIC GRANULOMATOUS DISEASE (CGD) AND NORMAL SUBJECTS BY DROPLET DIGITAL PCR (DDPCR)	Douglas B. Kuhns	NCI-Frederick
56	PROTEIN LOSING ENTEROPATHY IS A RISK FACTOR FOR INFECTIONS REQUIRING HOSPITALIZATION IN PATIENTS WITH FONTAN	Sarah Kogan Nicholas	Baylor College of Medicine
57	ELIMINATING NON-PATHOGENIC VARIATIONS FROM HUMAN EXOMES USING BLACKLISTS	Patrick Maffucci	Icahn School of Medicine at Mount Sinai
58	REFRACTORY AUTOIMMUNE CYTOPENIA LINKED TO VARICELLA INFECTION IN A CHILD WITH RAG DEFICIENCY	Aniko Eva Malik	Department of Pediatrics Semmelweis University



## POSTER LISTING

Poster	Poster Title	Name	Affiliation
59	POOR IMMUNE RECONSTITUTION FOLLOWING MATCHED SIBLING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR X-LINKED LYMPHOPROLIFERATIVE DISORDER (XLP): SHOULD WE RECONSIDER MATCHED CARRIER SIBLINGS AS HSCT DONORS IN X-LINKED IMMUNE DEFICIENCY?	Anu Mallapaty	Children's Healthcare of Atlanta, Emory University School of Medicine
60	A NOVEL DOMINANT NEGATIVE IKZF1 MUTATION C.476A>G (N159S) LEADS TO A COMBINED IMMUNE DEFICIENCY WITH ABSENT B CELLS AND ABNORMAL T CELL MATURATION AND FUNCTION	Rebecca Marsh	Cincinnati Children's Hospital Medical Center
61	AIRE AND IL-7 RECEPTOR COMPOUND HETEROZYGOUS MUTATIONS RESULTING IN A NOVEL PRESENTATION OF AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY (APECED)	Rushita Mehta	Montefiore Medical Center
62	CLINICAL FEATURES AND TREATMENT RESPONSES OF AUTOIMMUNE CYTOPENIAS WITH PRIMARY IMMUNODEFICIENCY AT A TERTIARY PEDIATRIC CARE FACILITY	Anna K. Meyer	Johns Hopkins All Children's Hospital
63	SEVERE VIRAL INFECTIONS: DO NOT FORGET ADENOSINE DEAMINASE 2 DEFICIENCY (DADA2).	Isabelle Meyts	University Hospitals Leuven
64	ALPS AND GAUCHER DISEASE. A CLINICAL AND BIOCHEMICAL OVERLAP	Maurizio Miano	IRCCS Istituto Giannina Gaslini
65	SINGLE/MULTI-LINEAGE BONE MARROW FAILURES SECONDARY TO PIDs-RELATED KNOWN/NOVEL MUTATIONS. A SINGLE CENTER EXPERIENCE.	Maurizio Miano	IRCCS Istituto Giannina Gaslini
66	BONE MARROW FAILURE SECONDARY TO ADA2 DEFICIENCY IN ADULT SIBLINGS	Thomas F. Michniacki	University of Michigan, C.S. Mott Children's Hospital
67	NOVEL MISSENSE MUTATION IN X-LINKED INHIBITOR OF APOPTOSIS (XIAP) LEADING TO THE DEVELOPMENT OF GRANULOMATOUS INTERSTITIAL LUNG DISEASE (GLILD)	Ranjeet Minocha	Medical College of Wisconsin
68	A CASE OF UNEXPLAINED MONTHLY FEVERS	Roshni Naik	SUNY Downstate Medical Center
69	NEW INSIGHTS FROM TRANSCRIPTOMIC ANALYSIS OF INTERFERON-GAMMA TREATED LEUKOCYTES FROM CHRONIC GRANULOMATOUS DISEASE AND INTERFERON-GAMMA RECEPTOR DEFICIENCY PATIENTS	Antonio Condino-Neto	University of Sao Paulo
70	EVALUATION OF THE OUTCOMES OF PROPHYLACTIC ANTIBIOTICS AND IMMUNOGLOBULIN REPLACEMENT IN PATIENTS WITH SPECIFIC ANTIBODY DEFICIENCY	An Nguyen	Baylor College of Medicine
71	INTRAVENOUS IMMUNOGLOBULIN-RELATED HEMOLYSIS IN KAWASAKI DISEASE: CASE REPORT AND REVIEW OF LITERATURE	Rofida Nofal	St. John Providence Children's Hospital
72	IDENTIFYING PREDICTORS OF PRIMARY IMMUNODEFICIENCY (PID) IN INFLAMMATORY BOWEL DISEASE (IBD)	Mei-Sing Ong	Harvard Medical School, Boston Children's Hospital
73	THE CHANGING FACE OF COMPLETE DIGEORGE ANOMALY: ATHYMIC PATIENTS WITH CHARGE SYNDROME	Grace Toledo Padron	Duke University Medical Center
74	EFFICACY, SAFETY, AND TOLERABILITY OF THE NEW HUMAN SUBCUTANEOUS IMMUNOGLOBULIN (SCIG 20%) IN PEDIATRIC PATIENTS (PTS) WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) DURING THE NORTH AMERICAN (NA) PHASE 2/3 STUDY	Kenneth Paris	LSU Health Sciences Center

## POSTER LISTING

Poster	Poster Title	Name	Affiliation
75	SAFETY/TOLERABILITY OF THE NEW HUMAN SUBCUTANEOUS IMMUNOGLOBULIN (SCIG 20%) IN PEDIATRIC PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD)	Kenneth Paris	LSU Health Sciences Center
76	COMMON ANTIGEN ANTIBODY MEASUREMENTS FOR ASSESSMENT OF HUMORAL IMMUNITY	Antony Parker	The Binding Site Group Ltd.
77	THE RESPONSE TO TYPHI VI VACCINATION IS COMPROMISED IN INDIVIDUALS WITH ANTIBODY DEFICIENCY	Antony Parker	The Binding Site Group Ltd.
78	EVOLUTION OF IMMUNODEFICIENCY IN A PATIENT WITH KABUKI SYNDROME.	Bhumika Patel	University of South Florida
79	IMMUNODEFICIENCY IN MIRAGE SYNDROME	Jay P. Patel	Seattle Children's Hospital
80	CD40/CD40L PATHWAY IS ASSOCIATED WITH INCREASED NEUTROPHIL EXTRACELLULAR TRAPS RELEASE IN BEHÇET'S DISEASE	Sandro Felix Perazzio	Federal University of Sao Paulo, University of Washington and Center for Immunity and Immunotherapies/Seattle Children's Research Institute
81	CD40/CD40L PATHWAY PLAYS A ROLE IN INCREASED NEUTROPHIL ACTIVATION IN BEHÇET'S DISEASE	Sandro Felix Perazzio	Federal University of Sao Paulo, University of Washington and Center for Immunity and Immunotherapies/Seattle Children's Research Institute
82	GRANULOMATOUS INTERSTITIAL LUNG DISEASE IN COMMON VARIABLE IMMUNODEFICIENCY: A CASE SERIES OF PATIENTS TREATED WITH RITUXIMAB AS A SINGLE AGENT	Deena Pourang	Kaiser Permanente Los Angeles Medical Center
83	THE EVALUATION OF THE HEALTH-RELATED QUALITY OF LIFE USING THE CVID_QOL SURVEY IN PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY: IMPACT OF CLINICAL, IMMUNOLOGICAL AND THERAPY-RELATED FACTORS ON THE BURDEN OF DISEASE	Federica Pulvirenti	Sapienza, University of Rome
84	AN UNUSUAL PRESENTATION OF A RARE COMBINED IMMUNODEFICIENCY	Andrea A. Ramirez	Baylor College of Medicine / Texas Children's Hospital
85	IMMUNE DYSREGULATION IN WEST NILE VIRUS ENCEPHALITIS CAUSING OPSOCLONUS-MYOCLONUS SYNDROME (OMS)	Erin Wahle Rasmussen	University of Iowa Hospitals and Clinics
86	SELECTIVE IgA DEFICIENCY (SigAD): AN UPDATE ON THE CLINICAL AND IMMUNOLOGICAL CHARACTERIZATION OF A COHORT OF COLOMBIAN PATIENTS.	Jose Luis Franco Restrepo	Universidad de Antioquia
87	A GLOBAL NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY (PASS) OF HYQVIA IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD)	Arye Rubenstein	Albert Einstein College of Medicine
88	CVID MASQUERADING AS LYMPHOMA: TWO CASE REPORTS	Tamar N. Rubin	University of Manitoba
89	X-LINKED AGAMMAGLOBULINEMIA (XLA) DIAGNOSED IN VIETNAMESE TEENAGER WHO PRESENTED WITH GASTROINTESTINAL DISEASE AND FOUND TO HAVE A NOVEL BRUTON'S TYROSINE KINASE (BTK) GENE MUTATION	Tamar N. Rubin	University of Manitoba
90	PRESENCE OF IMMUNE DEFICIENCY INCREASES THE RISK OF HOSPITALIZATION IN PATIENTS WITH NOROVIRUS INFECTION	Keith Sacco	Mayo Clinic Jacksonville
91	CORD BLOOD TRANSPLANTATION DOES NOT AMELIORATE MEVALONATE KINASE DEFICIENCY PHENOTYPE DESPITE FULL ENGRAFTMENT: A CASE REPORT	Blachy J Dávila Saldaña	Children's National Medical Center

## POSTER LISTING

Poster	Poster Title	Name	Affiliation
92	CRYPTOCOCCAL SEPSIS AS INITIAL PRESENTATION OF CD40L DEFICIENCY	Blachy J Dávila Saldaña	Children's National Medical Center
93	CLINICAL SPECTRUM OF A BRAZILIAN COHORT OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE $\Delta$ SYNDROME TYPE 1.	Gesmar Segundo	Seattle Children's Institute Research
94	ORAL, PERIANAL AND COLONIC ULCERS: AN UNUSUAL PRESENTATION IN AN INFANT WITH A NOVEL MUTATION IN THE WAS GENE	Gesmar Segundo	Seattle Children's Institute Research
95	FOLLOW UP DURING 6 YEARS OF 48 PATIENTS WITH SUBCUTANEOUS IMMUNOGLOBULIN TREATMENT BY PUSH AS REPLACEMENT AND IMMUNOMODULATORY THERAPY.	Analía Gisela Seminario	Ricardo Gutiérrez Children's Hospital
96	NEW CHALLENGES IN AGAMMAGLOBULINEMIC PATIENTS WITH ENTEROVIRUS	Analía Gisela Seminario	Ricardo Gutiérrez Children's Hospital
97	A CASE SERIES: CLUES TO A DIAGNOSIS OF CHRONIC GRANULOMATOUS DISEASE IN PATIENTS PRESENTING WITH HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS	Shanmuganathan Chandrakasan	Emory University School of Medicine
98	A CLINICOPATHOLOGICAL STUDY OF COMMON VARIABLE IMMUNE DEFICIENCY (CVID) PATIENTS MISDIAGNOSED WITH LYMPHOMA.	Tukisa D. Smith	Icahn School of Medicine at Mount Sinai
99	CEREBELLAR DEGENERATION IN A PATIENT WITH IPEX SYNDROME	Ariane Soldatos	National Institute of Neurological Disorders and Stroke
100	CLASS SWITCH MEMORY B CELLS ARE LOW IN 30% OF PATIENTS WITH RECURRENT INFECTIONS BUT NOT IN HEALTHY CONTROLS.	Ricardo Sorensen	Louisiana State University Health Sciences Center
101	THROMBOCYTOPENIA AS INITIAL PRESENTATION OF IKAROS DEFICIENCY ASSOCIATED WITH A NOVEL IKZF1 MUTATION	Panida Sriaroon	Johns Hopkins All Children's Hospital; University of South Florida Morsani College of Medicine
102	SAFETY AND TOLERABILITY DURING CLINICAL TRIALS OF THE NEW SUBCUTANEOUS IMMUNOGLOBULIN 20% FORMULATION (SCIG 20%) IN PATIENTS WITH PIDD IN EUROPE AND NORTH AMERICA	Daniel Suez	Allergy, Asthma & Immunology Clinic
103	LEUKOCLASTIC VASCULITIS IN COMPLEMENT DEFICIENCY TEMPORALLY ASSOCIATED WITH INTRAVENOUS GAMMAGLOBULIN THERAPY	Sara E Sussman	LSUHSC-New Orleans
104	IKBA GAIN-OF-FUNCTION MUTATION IN A FEMALE PRESENTING WITH INFECTIONS AND HYPER IgM, BUT WITHOUT ECTODERMAL DYSPLASIA.	Cristina Swanson	University of Washington and Seattle Children's Hospital
105	MULTIPLE INTESTINAL ATRESIA WITH COMBINED IMMUNODEFICIENCY	Bahar Torabi	Research Institute of McGill University Health Centre
106	ANALYSES OF PATIENTS (PTS) WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) TREATED BY DIFFERENT MODES OF ADMINISTRATION OF IMMUNOGLOBULIN (IG) THERAPY DURING THREE CONSECUTIVE STUDIES	Richard L. Wasserman	Dallas Allergy
107	EVALUATION OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS (PK) OF GAMMAPLEX® 10% VERSUS GAMMAPLEX® 5% IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PID)	Richard L. Wasserman	Dallas Allergy
108	PARTIAL RAG DEFICIENCY IN A CHILD WITH AUTOIMMUNE CYTOPENIA AND FEATURES OF AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME (ALPS)	Emma Westermann - Clark	University of South Florida Morsani College of Medicine

## POSTER LISTING

Poster	Poster Title	Name	Affiliation
109	POPULATION PHARMACOKINETIC (PK) MODELING AND SIMULATION OF VARIOUS DOSING INTERVALS AND DETERMINATION OF THE DOSE ADJUSTMENT FACTOR AFTER SC ADMINISTRATION OF IMMUNOGLOBULIN 20% (SCIG 20%) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD)	Leman Yel	Shire
110	COMMON VARIABLE IMMUNODEFICIENCY (CVID) IN ADULTS: SINGLE-CENTER FIRST YEAR EXPERIENCE IN CALI, COLOMBIA.	Andres F Zea-Vera	Universidad del Valle
111	IDENTIFICATION OF GENETIC SUSCEPTIBILITY VARIANTS FOR SEVERE VIRAL RESPIRATORY INFECTIONS IN CHILDREN	Yu Zhang	National Institute of Allergy and Infectious Diseases, National Institutes of Health
112	A NOVEL CASE OF A PATIENT WITH CYSTIC FIBROSIS AND OMENN SYNDROME	Jessica Zibert	University of Kansas Department of Allergy/Immunology
113	INTERIM RESULTS OF A NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY (PASS) ON THE LONG-TERM SAFETY OF SCIG 10% INFUSION FACILITATED WITH RECOMBINANT HUMAN HYALURONIDASE (rHUPH20) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) IN EUROPE (EU)	Brent Bialik	Shire
114	LOW T CELL RECEPTOR EXCISION CIRCLES (TREC) ON ROUTINE NEWBORN SCREENING (NBS) LEADING TO AN EARLY DIAGNOSIS OF PROPERDIN DEFICIENCY CARRIAGE	Yasmin Hamzavi Abedi	Hofstra Northwell School of Medicine

## SPONSORS

### THANK YOU TO OUR SUPPORTERS!

#### PREMIUM

Shire  
Grifols

#### PLATINUM

CSL Behring  
Horizon Pharma

#### GOLD

ADMA Biologics

#### SILVER

Immune Deficiency Foundation  
USIDNET

#### BRONZE

Celgene  
Coram CVS Specialty Infusion Services  
Jeffrey Modell Foundation  
Leadiant Biosciences, Inc.  
Robert A. Good Society  
Seattle Children's Research Institute

# 2017 CIS School in Primary Immunodeficiency Diseases

GALVESTON, TEXAS • OCTOBER 19-22, 2017



**Calling all Fellows**  
Submit an application today

**CIS** Clinical  
Immunology  
Society





# CIS 2018 Annual Meeting:

Immune Deficiency and Dysregulation  
North American Conference

SAVE THE DATE



April 26-29, 2018 🍁 Sheraton Centre Toronto 🍁 Toronto, Canada